Pierre Fabre's BRAFTOVI Receives Positive CHMP Opinion for Colorectal Cancer Treatment
In a significant step for oncology, Les Laboratoires Pierre Fabre has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion regarding the approval of BRAFTOVI® (encorafenib). The therapy, in combination with cetuximab and FOLFOX (which comprises fluorouracil, leucovorin, and oxaliplatin), is recommended as a first-line treatment for adult patients suffering from metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This promising news is backed by the results from the phase 3 BREAKWATER trial, which demonstrated the combination’s potential in significantly improving patient outcomes. The trial specifically analyzed patients who had not undergone prior treatment for their metastatic disease.
The BREAKWATER study revealed statistically significant improvements in primary endpoints, including the objective response rate (ORR) and progression-free survival (PFS). Furthermore, the combination therapy also achieved a notable enhancement in overall survival (OS), indicating a 51% reduction in the risk of death compared to standard chemotherapy regimens, which may or may not include bevacizumab.
Eric Ducournau, General Director of Pierre Fabre Laboratories, expressed optimism about the CHMP’s endorsement, labeling it a pivotal moment for the targeted therapy landscape, particularly for patients with the BRAFV600E mutation. If the European Commission affirms the CHMP opinion later this year, this regimen will emerge as the first and only targeted therapy for first-line treatment in this specific patient population. This development could represent a critical advancement in addressing an unmet medical need within colorectal cancer treatment, emphasizing Pierre Fabre's commitment to pioneering significant innovations in oncology. Ducournau highlighted the company's dedication to collaborating closely with the scientific and medical communities to enhance treatment solutions for patients battling this challenging illness.
The anticipated decision from the European Commission is expected later in 2026. If granted authorization, BRAFTOVI, in conjunction with cetuximab and mFOLFOX6, will mark a substantial milestone for both patients and healthcare providers in the management of metastatic colorectal cancer associated with the BRAFV600E mutation. The positive outcome of the BREAKWATER trial not only emphasizes the efficacy of BRAFTOVI but also bolsters Pierre Fabre’s position as a leader in innovative oncology solutions. As this approval journey unfolds, the oncology community remains hopeful about the transformative potential of this targeted therapy in improving patient survival rates and quality of life.
The BREAKWATER study revealed statistically significant improvements in primary endpoints, including the objective response rate (ORR) and progression-free survival (PFS). Furthermore, the combination therapy also achieved a notable enhancement in overall survival (OS), indicating a 51% reduction in the risk of death compared to standard chemotherapy regimens, which may or may not include bevacizumab.
Eric Ducournau, General Director of Pierre Fabre Laboratories, expressed optimism about the CHMP’s endorsement, labeling it a pivotal moment for the targeted therapy landscape, particularly for patients with the BRAFV600E mutation. If the European Commission affirms the CHMP opinion later this year, this regimen will emerge as the first and only targeted therapy for first-line treatment in this specific patient population. This development could represent a critical advancement in addressing an unmet medical need within colorectal cancer treatment, emphasizing Pierre Fabre's commitment to pioneering significant innovations in oncology. Ducournau highlighted the company's dedication to collaborating closely with the scientific and medical communities to enhance treatment solutions for patients battling this challenging illness.
The anticipated decision from the European Commission is expected later in 2026. If granted authorization, BRAFTOVI, in conjunction with cetuximab and mFOLFOX6, will mark a substantial milestone for both patients and healthcare providers in the management of metastatic colorectal cancer associated with the BRAFV600E mutation. The positive outcome of the BREAKWATER trial not only emphasizes the efficacy of BRAFTOVI but also bolsters Pierre Fabre’s position as a leader in innovative oncology solutions. As this approval journey unfolds, the oncology community remains hopeful about the transformative potential of this targeted therapy in improving patient survival rates and quality of life.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.